JPH11506737A - 小細胞肺ガンを治療または検出するためのコノトキシンペプチドu002およびmiiの使用 - Google Patents
小細胞肺ガンを治療または検出するためのコノトキシンペプチドu002およびmiiの使用Info
- Publication number
- JPH11506737A JPH11506737A JP9500831A JP50083197A JPH11506737A JP H11506737 A JPH11506737 A JP H11506737A JP 9500831 A JP9500831 A JP 9500831A JP 50083197 A JP50083197 A JP 50083197A JP H11506737 A JPH11506737 A JP H11506737A
- Authority
- JP
- Japan
- Prior art keywords
- conotoxin
- mii
- sclc
- peptides
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title claims abstract description 60
- 208000000587 small cell lung carcinoma Diseases 0.000 title claims abstract description 60
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 116
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 57
- 108050003126 conotoxin Proteins 0.000 title description 36
- 108091058551 α-conotoxin Proteins 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 20
- 239000003053 toxin Substances 0.000 claims description 13
- 231100000765 toxin Toxicity 0.000 claims description 13
- 108700012359 toxins Proteins 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 7
- 101710194973 Alpha-conotoxin MII Proteins 0.000 claims description 6
- AAQUWIGGQCWDOE-QANPVJDHSA-N chembl558599 Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(NC[C@@H](CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1)C(N)=O)=O)CC(C)C)C1=CN=CN1 AAQUWIGGQCWDOE-QANPVJDHSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract description 22
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract description 22
- 230000027455 binding Effects 0.000 abstract description 13
- 230000002232 neuromuscular Effects 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 230000001537 neural effect Effects 0.000 abstract description 7
- 239000003550 marker Substances 0.000 abstract description 3
- 239000011347 resin Substances 0.000 description 25
- 229920005989 resin Polymers 0.000 description 25
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 239000002435 venom Substances 0.000 description 15
- 231100000611 venom Toxicity 0.000 description 15
- 210000001048 venom Anatomy 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 231100000614 poison Toxicity 0.000 description 13
- 239000002574 poison Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 241000237970 Conus <genus> Species 0.000 description 10
- 241000237536 Mytilus edulis Species 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229940104302 cytosine Drugs 0.000 description 8
- 235000020638 mussel Nutrition 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- YXBQTKPMFURSAT-LHOQNBIESA-N (2S)-2-[[(2S)-6-amino-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-[[(2R,5S)-5-[(2-aminoacetyl)amino]-8-(diaminomethylideneamino)-4-oxo-2-(sulfanylmethyl)octanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]hexanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanediamide Chemical compound C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CS)NC(=O)[C@H](CS)CC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(N)=O YXBQTKPMFURSAT-LHOQNBIESA-N 0.000 description 6
- 101710135826 Alpha-conotoxin MI Proteins 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 6
- 210000000287 oocyte Anatomy 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 5
- 210000000715 neuromuscular junction Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 210000003192 autonomic ganglia Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- -1 hydroxy-prolyl residue Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 4
- 108091058550 ω-conotoxin Proteins 0.000 description 4
- HWYLVHOPQMLNRJ-NAKBKFBQSA-N 76862-65-2 Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H](CC(N)=O)C(=O)N3CCC[C@H]3C(=O)N[C@H](C(N[C@@H](CSSC[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N2)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)C)C(N)=O)C1=CC=C(O)C=C1 HWYLVHOPQMLNRJ-NAKBKFBQSA-N 0.000 description 3
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 3
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 3
- FHVUTHWUIUXZBY-QLANQDRJSA-N 147794-23-8 Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 FHVUTHWUIUXZBY-QLANQDRJSA-N 0.000 description 2
- 101710135856 Alpha-conotoxin GI Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000237971 Conus magus Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003127 mollusc venom Substances 0.000 description 2
- SMBBZHGTZJNSRQ-UHFFFAOYSA-N n'-(6,6-dichlorohexyl)methanediimine Chemical group ClC(Cl)CCCCCN=C=N SMBBZHGTZJNSRQ-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 108091058549 μ-conotoxin Proteins 0.000 description 2
- YNWQPDMRDQFPAV-HQGLSJOVSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s,3r)-2-[[2-[[(2r)-2-[[2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[2-[[(2r)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropan Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN)C1=CC=C(O)C=C1 YNWQPDMRDQFPAV-HQGLSJOVSA-N 0.000 description 1
- OQFSQFPPLPISGP-REOHCLBHSA-N (2s)-2-aminoethane-1,1,2-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-REOHCLBHSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- 101710194170 Alpha-conotoxin SII Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000237972 Conus geographus Species 0.000 description 1
- 241000237976 Conus striatus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 241000251733 Tetronarce californica Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 238000007265 chloromethylation reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- XYWDPYKBIRQXQS-UHFFFAOYSA-N di-isopropyl sulphide Natural products CC(C)SC(C)C XYWDPYKBIRQXQS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- WXEHBUMAEPOYKP-UHFFFAOYSA-N methylsulfanylethane Chemical compound CCSC WXEHBUMAEPOYKP-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 108091058548 κ-conotoxin Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.医薬上許容される担体中にMIIおよびU002よりなる群から選択され るα-コノトキシンの有効量を含んでなる医薬組成物を投与することを特徴とす る小細胞肺ガンを患う患者を治療する方法。 2.医薬上許容される担体中にMIIおよびU002よりなる群から選択され るα-コノトキシンの有効量を含んでなる医薬組成物を投与することを特徴とす る小細胞肺ガン不死化(proliferation)を阻害する方法。 3.MIIおよびU002よりなる群から選択される標識したα-コノトキシ ンを対象に注射し、腫瘍の存在を検出することを特徴とする小細胞肺ガン腫瘍の 存在を検出する方法。 4.MIIおよびU002よりなる群から選択される標識したα-コノトキシ ンを対象に注射し、腫瘍の存在を検出することを特徴とする小細胞肺ガン腫瘍の 位置を検出する方法。 5.小細胞肺ガンを患う患者を治療する医薬組成物を調製するためのα-コノ トキシンMIIまたはU002の使用。 6.小細胞肺ガン不死化を阻害する医薬組成物を調製するためのα-コノトキ シンMIIまたはU002の使用。 7.小細胞肺ガン腫瘍の存在または位置を検出する診断組成物を調製するため のα-コノトキシンMIIまたはU002の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/487,174 US5595972A (en) | 1993-06-29 | 1995-06-07 | Conotoxin peptides |
US08/487,174 | 1995-06-07 | ||
PCT/US1996/007962 WO1996040211A1 (en) | 1995-06-07 | 1996-06-04 | Use of conotoxin peptides u002 and mii for treating or detecting small-cell lung carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11506737A true JPH11506737A (ja) | 1999-06-15 |
Family
ID=23934710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9500831A Withdrawn JPH11506737A (ja) | 1995-06-07 | 1996-06-04 | 小細胞肺ガンを治療または検出するためのコノトキシンペプチドu002およびmiiの使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5595972A (ja) |
EP (1) | EP0844883A4 (ja) |
JP (1) | JPH11506737A (ja) |
AU (1) | AU695055B2 (ja) |
CA (1) | CA2223737A1 (ja) |
WO (1) | WO1996040211A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
WO1998003541A1 (en) * | 1996-07-22 | 1998-01-29 | University Of Utah Research Foundation | Conantokins |
US5780433A (en) * | 1996-12-06 | 1998-07-14 | University Of Utah Research Foundation | Use of α-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release |
AU1114399A (en) * | 1997-10-24 | 1999-05-17 | Case Western Reserve University | Interaction of alpha-conotoxin peptides with neuronal nicotinic acetylcho line receptors |
AU2091799A (en) | 1997-12-31 | 1999-07-19 | University Of Utah Research Foundation | Uses of alpha-conotoxin peptides |
US5969096A (en) * | 1998-06-26 | 1999-10-19 | The Salk Institute For Biological Studies | Conotoxin peptides |
US20040204362A1 (en) * | 1999-01-22 | 2004-10-14 | The University Of Utah Research Foundation | Alpha-conotoxin peptides |
EP1147130A4 (en) * | 1999-01-29 | 2004-09-29 | Univ Utah Res Found | ALPHA-CONOTOXIN PEPTIDES |
US6797808B1 (en) | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
IL148053A0 (en) | 1999-08-10 | 2002-09-12 | Uab Research Foundation | Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occuring conotoxins |
AU2002245340A1 (en) * | 2001-01-29 | 2002-08-12 | Cognetix, Inc. | B-superfamily conotoxins |
WO2003095477A2 (en) * | 2002-03-15 | 2003-11-20 | Board Of Regents, The University Of Texas System | Miniprotein ligands and other polypeptides and methods for making and using same |
WO2004016586A2 (en) * | 2002-08-16 | 2004-02-26 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
JP4095494B2 (ja) * | 2003-05-30 | 2008-06-04 | キヤノン株式会社 | 眼科画像処理装置及び処理方法 |
US10633417B2 (en) * | 2013-05-31 | 2020-04-28 | University Of Utah Research Foundation | Conotoxin peptides, pharmaceutical compositions and uses thereof |
EP3215172B1 (en) | 2014-11-07 | 2023-04-26 | Kineta Chronic Pain, Llc. | Modifications and uses of conotoxin peptides |
CN117843749B (zh) * | 2024-03-04 | 2024-05-28 | 成都圣诺生物多肽科技有限公司 | 一种精氨酸/赖氨酸多肽的固相合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514774A (en) * | 1993-06-29 | 1996-05-07 | University Of Utah Research Foundation | Conotoxin peptides |
US5633347A (en) * | 1993-06-29 | 1997-05-27 | University Of Utah Research Foundation | Conotoxin peptides |
-
1995
- 1995-06-07 US US08/487,174 patent/US5595972A/en not_active Expired - Lifetime
-
1996
- 1996-06-04 AU AU62503/96A patent/AU695055B2/en not_active Ceased
- 1996-06-04 WO PCT/US1996/007962 patent/WO1996040211A1/en not_active Application Discontinuation
- 1996-06-04 EP EP96921234A patent/EP0844883A4/en not_active Withdrawn
- 1996-06-04 CA CA002223737A patent/CA2223737A1/en not_active Abandoned
- 1996-06-04 JP JP9500831A patent/JPH11506737A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0844883A4 (en) | 1999-03-31 |
EP0844883A1 (en) | 1998-06-03 |
CA2223737A1 (en) | 1996-12-19 |
US5595972A (en) | 1997-01-21 |
WO1996040211A1 (en) | 1996-12-19 |
AU695055B2 (en) | 1998-08-06 |
AU6250396A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0728146B1 (en) | Conotoxin peptides | |
JPH11506737A (ja) | 小細胞肺ガンを治療または検出するためのコノトキシンペプチドu002およびmiiの使用 | |
US5633347A (en) | Conotoxin peptides | |
US6265541B1 (en) | Uses of α-conotoxin peptides | |
US5739276A (en) | Conotoxin peptides | |
US5670622A (en) | Conotoxin peptide PIIIA | |
JP4212651B2 (ja) | サソリ由来神経ペプチド | |
US20030109670A1 (en) | Cone snail peptides | |
US5866682A (en) | Conopeptides AuIA, AuIB and AuIC | |
US5591821A (en) | Omega-conotoxin peptides | |
US5589340A (en) | Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides | |
KR20040096554A (ko) | 경색방지 분자 | |
WO1999033865A1 (en) | Contryphan peptides | |
JP2002534996A (ja) | アルファ−コノトキシン・ペプチド | |
US6441132B1 (en) | Contryphan peptides | |
US20080274976A1 (en) | Uses of novel potassium channel blockers | |
US6624288B1 (en) | Gamma-conopeptides | |
AU768091B2 (en) | Tau-conotoxin peptides | |
Ramilo | McIntosh et al. | |
Burlingame et al. | Fainzilber et al. | |
AU2002253924A1 (en) | Cone snail peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080402 Year of fee payment: 9 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080402 Year of fee payment: 9 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090402 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100402 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110402 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |